基于TCP早期退缩指数可准确预测直肠癌新辅助放化疗后的结局
该研究纳入65例接受早期退缩引导自适应增强放疗的直肠癌患者,评估基于TCP的早期退缩指数ERITCP对长期无病生存的预测价值。中位随访47个月时,含ERITCP的模型对无远处转移生存的判别力AUC为0.86,显著高于常规模型0.75(p=0.05)。ERITCP也是唯一与总生存和无局部区域复发生存显著相关的变量。
要点
- ERITCP可预测直肠癌新辅助放化疗后的长期无远处转移生存。
- 含ERITCP模型AUC 0.86,优于常规模型0.75(p=0.05)。
- 5-FU剂量>90%对无远处转移生存有独立影响。
核心结论
- ERITCP可预测直肠癌放化疗后的长期无远处转移生存,且5-FU剂量对其有独立影响。
- 该结果为ERITCP应用于治疗个体化迈出第一步,仍需独立队列验证。
研究设计与样本
- 回顾性分析65例接受早期退缩引导自适应增强放疗的直肠癌患者数据。
- 放疗方案为41.4 Gy/18次(2.3 Gy/次),最后6次对残留GTV同步加量(3 Gy/次,Dmean 45.6 Gy)。
- 化疗包含奥沙利铂和5-氟尿嘧啶(5-FU)。
- 基于治疗前和治疗一半时的T2加权MRI勾画GTV(Vpre、Vhalf),计算ERITCP。
- 采用Cox回归模型比较不含/含ERITCP的CONV_model与REGR_model的判别力。
主要发现
- 中位随访47个月时,总生存、无局部区域复发生存和无远处转移生存分别为94%、95%和78%。
- CONV_model包含病理完全缓解或临床完全缓解后拒绝手术(HR 0.15,p=0.07)和5-FU剂量>90%(HR 0.29,p=0.03),AUC=0.75。
- REGR_model包含ERITCP(HR 1.019,p<0.0001)和5-FU剂量>90%(HR 0.18,p=0.005),AUC=0.86,显著高于CONV_model(p=0.05)。
- 按ERITCP最佳截断值和5-FU剂量(> vs <90%)分层,47个月无远处转移生存分别为100%/69%/0%(两个/一个/零个有利因素,p=0.0002)。
- ERITCP也是唯一与总生存(p=0.01)和无局部区域复发生存(p=0.03)显著相关的变量。
关键数值与推荐
- ERITCP计算公式为-ln[(1 - (Vhalf/Vpre))Vpre]。
- REGR_model中ERITCP的HR为1.019(p<0.0001),5-FU剂量>90%的HR为0.18(p=0.005)。
- CONV_model中病理完全缓解或临床完全缓解后拒绝手术的HR为0.15(p=0.07),5-FU剂量>90%的HR为0.29(p=0.03)。
- 按ERITCP最佳截断值和5-FU剂量>90%分层,47个月无远处转移生存为100%/69%/0%(p=0.0002)。
临床怎么用
- ERITCP可作为一种潜在生物标志物,用于预测直肠癌新辅助放化疗后的长期无远处转移生存。
- 5-FU剂量>90%与更好的无远处转移生存相关,提示化疗剂量强度的重要性。
- ERITCP有望辅助治疗个体化决策,但需在独立队列中进一步验证。
局限性
- 本研究为单中心回顾性分析,样本量仅65例。
- 由于事件数过少,多变量分析仅聚焦于无远处转移生存。
- ERITCP的应用仍需独立队列确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: An early tumor regression index (ERITCP) was previously introduced and found to predict pathological response after neo-adjuvant radio-chemotherapy of rectal cancer. ERITCP was tested as a potential biomarker in predicting long-term disease-free survival. MATERIALS AND METHODS: Data of 65 patients treated with an early regression-guided adaptive boosting technique (ART) were available. Overall, loco-regional relapse-free and distant metastasis-free survival (OS, LRFS, DMFS) were considered. Patients received 41.4 Gy in 18 fractions (2.3 Gy/fr), including ART concomitant boost on the residual GTV during the last 6 fractions (3 Gy/fr, Dmean: 45.6 Gy). Chemotherapy included oxaliplatin and 5-fluorouracil (5-FU). T2-weighted MRI taken before (MRIpre) and at half therapy (MRIhalf) were available and GTVs were contoured (Vpre, Vhalf). The parameter ERITCP = -ln[(1 - (Vhalf/Vpre))Vpre] was calculated for all patients. Cox regression models were assessed considering several clinical and histological variables. Cox models not including/including ERITCP (CONV_model and REGR_model respectively) were assessed and their discriminative power compared. RESULTS: At a median follow-up of 47 months, OS, LRFS and DMFS were 94%, 95% and 78%. Due to too few events, multivariable analyses focused on DMFS: the resulting CONV_model included pathological complete remission or clinical complete remission followed by surgery refusal (HR: 0.15, p = 0.07) and 5-FU dose >90% (HR: 0.29, p = 0.03) as best predictors, with AUC = 0.75. REGR_model included ERITCP (HR: 1.019, p < 0.0001) and 5-FU dose >90% (HR: 0.18, p = 0.005); AUC was 0.86, significantly higher than CONV_model (p = 0.05). Stratifying patients according to the best cut-off value for ERITCP and to 5-FU dose (> vs <90%) resulted in 47-month DMFS equal to 100%/69%/0% for patients with two/one/zero positive factors respectively (p = 0.0002). ERITCP was also the only variable significantly associated to OS (p = 0.01) and LRFS (p = 0.03). CONCLUSION: ERITCP predicts long-term DMFS after radio-chemotherapy for rectal cancer: an independent impact of the 5-FU dose was also found. This result represents a first step toward application of ERITCP in treatment personalization: additional confirmation on independent cohorts is warranted.
引用
- Fiorino C, Passoni P, Palmisano A, et al. Accurate outcome prediction after neo-adjuvant radio-chemotherapy for rectal cancer based on a TCP-based early regression index. Clin Transl Radiat Oncol. 2019. PMID: 31334366. doi:10.1016/j.ctro.2019.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。